ABCL vs RDNT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABCL · AbCellera Biologics$11.88 ▲ 6.74%
RDNT · RadNet$76.00 ▼ 2.58%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABCL +194.8%
- RDNT -6.0%
Head to head
| Metric | ABCL | RDNT |
|---|---|---|
| Price | $11.88 | $76.00 |
| Change today | ▲ 6.74% | ▼ 2.58% |
| Market cap | $3.85B | $5.98B |
| Return, 3 months | +27.2% | -1.7% |
| Return, year to date | +247.4% | +6.5% |
| Return, 1 year | +203.8% | -2.9% |
| P/E (TTM) | – | – |
| P/B | 4.3 | 5.5 |
| P/E percentile vs own 5y | 7th | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -76.3% | +25.0% |
| Net profit growth (YoY) | -59.6% | -12.1% |
| Gross margin | – | 11.5% |
| Operating margin | -318.8% | 4.0% |
| Net margin | -248.8% | -0.9% |
| Return on equity | -17.3% | -2.1% |
| Analyst target vs. price | +44.8% | +19.7% |
| Analyst buy share | 91% | 100% |
| RSI (14) | 48 | 58 |
| 30-day volatility | 85.9% | 41.8% |
| Max drawdown, 1 year | -51.8% | -38.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RDNT is the largest of the group by market value.
- ABCL has returned the most over the past year.
- RDNT is growing revenue fastest.
- RDNT keeps the most profit per dollar of sales.
- RDNT has been the calmest stock over the last 30 days.